Aprea Therapeutics Stock Price, News & Analysis (NASDAQ:APRE) $3.75 +0.06 (+1.63%) (As of 02:31 PM ET) Add Compare Share Share Today's Range$3.75▼$3.9550-Day Range$3.41▼$5.3352-Week Range$2.78▼$12.00Volume1,937 shsAverage Volume22,826 shsMarket Capitalization$14.03 millionP/E RatioN/ADividend YieldN/APrice Target$14.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Aprea Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside268.0% Upside$14.50 Price TargetShort InterestHealthy3.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.07) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector531st out of 935 stocksPharmaceutical Preparations Industry247th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingAprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.50, Aprea Therapeutics has a forecasted upside of 268.0% from its current price of $3.94.Amount of Analyst CoverageAprea Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.70% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Aprea Therapeutics has recently decreased by 3.26%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAprea Therapeutics does not currently pay a dividend.Dividend GrowthAprea Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APRE. Previous Next 2.7 News and Social Media Coverage News SentimentAprea Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aprea Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for APRE on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.90% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.62% of the stock of Aprea Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aprea Therapeutics are expected to grow in the coming year, from ($3.07) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aprea Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aprea Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAprea Therapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aprea Therapeutics Stock (NASDAQ:APRE)Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Read More APRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APRE Stock News HeadlinesNovember 17, 2023 | markets.businessinsider.comCapricor Therapeutics: Solid Financials and Promising DMD Trial Progression Support Buy RatingNovember 12, 2023 | markets.businessinsider.comVistaGen Therapeutics’ Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive AnalysisNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 11, 2023 | markets.businessinsider.comPromising Clinical Data and Financial Performance Validate Buy Rating for Aprea Therapeutics: An Analysis by Robert DriscollNovember 9, 2023 | msn.comAprea Therapeutics GAAP EPS of -$0.86November 9, 2023 | finance.yahoo.comAprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateOctober 16, 2023 | markets.businessinsider.comPositive Outlook for Aprea Therapeutics: Promising Developments and Safety Profile of ATRN-119 Bolster Buy RatingOctober 16, 2023 | finance.yahoo.comAprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality PortfolioNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 6, 2023 | markets.businessinsider.comPromising Outlook for Aprea Therapeutics: A Buy Rating Based on Upcoming Safety Data and Synthetic Lethal Targeting PotentialSeptember 21, 2023 | markets.businessinsider.comAprea Therapeutics (APRE) Gets a Buy from Maxim GroupSeptember 19, 2023 | finance.yahoo.comAprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 11, 2023 | finance.yahoo.comAprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 InhibitorsSeptember 6, 2023 | finance.yahoo.comAprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 24, 2023 | finance.yahoo.comMyelodysplastic Syndrome Drugs Global Market Report 2023August 24, 2023 | finance.yahoo.comAprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as ChairmanAugust 10, 2023 | finance.yahoo.comAprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business OperationsAugust 1, 2023 | seekingalpha.comRLFTF Relief Therapeutics Holding AGJune 14, 2023 | finance.yahoo.comAprea Therapeutics to Present at Maxim Virtual Healthcare ConferenceMay 30, 2023 | finance.yahoo.comAprea Therapeutics to Present at BIO International ConventionMay 17, 2023 | msn.comHC Wainwright & Co. Reiterates Aprea Therapeutics (APRE) Buy RecommendationMay 11, 2023 | marketwatch.comGlobal Targeting p53 Cancer Therapies Market Size 2023-2031 Competitive Landscape by Absolute Reports | with [86 Pages]May 8, 2023 | finance.yahoo.comAprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of DirectorsApril 24, 2023 | finance.yahoo.comBears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' NowApril 1, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for Aprea Therapeutics (APRE)March 31, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)March 31, 2023 | msn.comAprea Therapeutics GAAP EPS of -$0.92 beats by $2.30See More Headlines Receive APRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APRE CUSIPN/A CIK1781983 Webwww.aprea.com Phone617-463-9385FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$14.50 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+268.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,660,000.00 Net MarginsN/A Pretax Margin-2,330.88% Return on Equity-55.45% Return on Assets-45.57% Debt Debt-to-Equity RatioN/A Current Ratio6.15 Quick Ratio6.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.66 per share Price / Book0.41Miscellaneous Outstanding Shares3,740,000Free Float2,956,000Market Cap$14.74 million OptionableNot Optionable Beta0.77 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Oren Gilad Ph.D. (Age 54)Co-Founder, CEO, President and Director Comp: $520.84kMr. John P. Hamill CPA (Age 59)Senior VP, CFO, Principal Accounting Officer & Secretary Dr. Dansu Li Ph.D.Head of TechnologyDr. Lars B. Abrahmsen Ph.D. (Age 66)Senior VP & Chief Scientific Officer Dr. Michel Afargan Ph.D.Head of Pharmacology DevelopmentMr. Ze'ev Weiss B.Sc. (Age 61)C.P.A., Chief Business Advisor Ms. Andrea EpsteinControllerMore ExecutivesKey CompetitorsGeoVax LabsNASDAQ:GOVXAytu BioPharmaNASDAQ:AYTUVallon PharmaceuticalsNASDAQ:VLONOnconova TherapeuticsNASDAQ:ONTXVincerx PharmaNASDAQ:VINCView All CompetitorsInsiders & InstitutionsWalleye Capital LLCSold 11,271 shares on 11/21/2023Ownership: 2.204%Bernd R SeizingerBought 4,068 shares on 6/6/2023Total: $14,766.84 ($3.63/share)View All Insider TransactionsView All Institutional Transactions APRE Stock Analysis - Frequently Asked Questions Should I buy or sell Aprea Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APRE shares. View APRE analyst ratings or view top-rated stocks. What is Aprea Therapeutics' stock price target for 2024? 3 brokers have issued twelve-month price targets for Aprea Therapeutics' shares. Their APRE share price targets range from $9.00 to $20.00. On average, they anticipate the company's share price to reach $14.50 in the next year. This suggests a possible upside of 267.1% from the stock's current price. View analysts price targets for APRE or view top-rated stocks among Wall Street analysts. How have APRE shares performed in 2023? Aprea Therapeutics' stock was trading at $6.62 at the beginning of 2023. Since then, APRE stock has decreased by 40.3% and is now trading at $3.95. View the best growth stocks for 2023 here. When is Aprea Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our APRE earnings forecast. How were Aprea Therapeutics' earnings last quarter? Aprea Therapeutics, Inc. (NASDAQ:APRE) posted its quarterly earnings data on Monday, November, 8th. The company reported ($9.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($9.00). When did Aprea Therapeutics' stock split? Aprea Therapeutics's stock reverse split before market open on Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aprea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN). When did Aprea Therapeutics IPO? (APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO. Who are Aprea Therapeutics' major shareholders? Aprea Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Capital LLC (2.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Eyal C Attar, Gregory Alan Korbel and Lars B Abrahmsen. View institutional ownership trends. How do I buy shares of Aprea Therapeutics? Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:APRE) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.